A multicultural group practicing yoga together in a bright studio

Embody vs telos rx: GLP-1 Comparison 2026

Embody vs telos rx: pricing, medication type, clinical support, and which mid-market GLP-1 patient each program fits. Both programs’ prices verified July 2026 or later; each price carries its own date in the table below.

By RangeYourselfUpdated August 21, 20264 min read

Quick answer

Embody and telos rx both offer GLP-1 telehealth, but they package medication, support, and pricing differently. The right choice depends on whether you weight cost, clinical touch, or formulation flexibility highest.

Side-by-side comparison

Feature	Embody	telos rx
Best for	Personalized compounded blends and hands-on support	One integrated care team across GLP-1, hormones/longevity, sexual health, and recovery (peptide-led telehealth) rather than a single-indication weight-loss pure-play
Medication type	Compounded GLP-1 with personalization	Compounded semaglutide and tirzepatide (injectable, plus needle-free oral/sublingual and a microdosed tirzepatide) inside an integrated peptide-led telehealth menu; medical services by an independent US-licensed medical group (Arora Health Group)
Pricing model	Monthly subscription, formulation-tiered	Cash-pay subscription with 'first month low as' intro pricing per medication; the ongoing recurring rate is NOT published on the public site (funnel-gated at start.telosrx.com), no single defensible recurring price (Oak/LIV Body mechanism)
Semaglutide price	Compounded, $69/mo (limited-time promo, was $299), verified 2026-08-21; confirm current price at checkout. Standard/recurring price not publicly listed. (Same offer showed $99/mo and $149/mo promos on 2026-07-14, see price history.)	Compounded, advertised 'first month low as $49'; ongoing recurring rate not published (funnel-gated), confirm at enrollment
Tirzepatide price	Compounded tirzepatide / GLP-1+GIP, $119/mo (flat pricing shown on the verified offer page), verified 2026-08-21; no 'was' comparison price shown for tirzepatide specifically, confirm at signup.	Compounded, injectable advertised 'first month low as $99'; oral 'first month low as $49'; microdosed 'first month low as $69'; ongoing recurring rate not published, confirm at enrollment
Key watchout	Embody's published price is a live time-limited promo with no confirmed standing rate: it changed intra-day on 2026-07-14 ($99/mo AM, '$200 OFF, was $299', to $149/mo PM, '$150 OFF, was $299'), and by 2026-08-21 the same offer URL had dropped further to a new low. We rank it at its current verified purchasable price ($69/mo semaglutide) and label it a promo, confirm the exact cost at checkout. Custom blends also warrant scrutiny on ingredient transparency.	telos publishes only 'first month low as' intro figures (semaglutide $49, tirzepatide $99, oral tirzepatide $49, microdosed tirzepatide $69); the ongoing monthly rate is not shown on the public site and is confirmed inside the intake flow, confirm the real recurring price at enrollment. State availability is not published, no dispensing pharmacy is named, and shipped compounded medication is non-refundable.
Price checked	Checked by a person August 21, 2026 · an automated check re-read it September 3, 2026	Checked by a person July 17, 2026

When to choose Embody

You want a compounded program that personalizes the formulation
You're comfortable evaluating ingredient lists and provider transparency
You'd value bundled adjuncts (anti-nausea, B12, etc.) when offered
You're escalating dose and want a provider that adjusts with you

Check current Embody pricing →

When to choose telos rx

You want one integrated care team across GLP-1 weight loss, longevity/energy (NAD+), recovery (sermorelin), and sexual health (PT-141) rather than a single-indication program
You value an upfront 'compounded / not FDA-approved' disclosure and a LegitScript-certified telehealth platform
You're comfortable confirming the real ongoing monthly price at enrollment (telos publishes only 'first month low as' intro figures)
You want async care with a 5-minute online visit and a 100% refund if a clinician decides a GLP-1 isn't the right fit

Check current telos rx pricing →

Full reviews

Frequently asked questions

Is Embody cheaper than telos rx?

Neither Embody nor telos rx is uniformly cheaper, both publish dose-banded and formulation-banded pricing that depends on the exact product, dose, and any insurance pathway. Compare the specific tier you'd be on at each before deciding.

Which is better for semaglutide or tirzepatide, Embody or telos rx?

Both Embody and telos rx prescribe semaglutide and tirzepatide where appropriate. Choose based on how each program handles your target medication, not just the entry price.

Are Embody and telos rx compounded or brand-name?

Embody offers compounded glp-1 with personalization. telos rx offers compounded semaglutide and tirzepatide (injectable, plus needle-free oral/sublingual and a microdosed tirzepatide) inside an integrated peptide-led telehealth menu; medical services by an independent us-licensed medical group (arora health group). If you specifically want brand-name Wegovy or Zepbound, lean toward whichever explicitly supports brand access; if compounded is fine, both can typically meet that need.

Can I switch from Embody to telos rx?

Yes, switching between Embody and telos rx is straightforward in most states. You typically finish your current month, complete a new intake with the other provider, and they handle the prescription. Watch for overlap on auto-renewal billing and confirm any dose-tier or formulation differences with the new clinician before your next shipment.

Compare Embody and telos rx to other programs

Alert me when this gets cheaper

These prices move. Get one email when we publish a verified price drop, the programs on this list included. No spam. Unsubscribe any time.

Related guides

About compounded GLP-1 medicationsCompounded semaglutide and tirzepatide are not FDA-approved finished products. They are prepared by state-licensed 503A pharmacies or 503B outsourcing facilities and are not individually reviewed by the FDA for safety, effectiveness, or quality. Compounders describe these preparations as using the same active ingredient as the approved medicines; the FDA has warned that some compounded products use salt forms, semaglutide sodium or semaglutide acetate, that it considers different active ingredients from the approved drug, and has issued warning letters over marketing that presents a compounded preparation as interchangeable with an approved one. The FDA declared the semaglutide shortage resolved on February 21, 2025 and the tirzepatide shortage resolved in December 2024, so the shortage-era pathway for broad compounding of these drugs has ended. Compounding now proceeds under the ordinary rules: a 503A pharmacy compounding for an individual patient on a prescription, or a 503B outsourcing facility, which compounds in bulk under CGMP and FDA registration rather than per patient. Those rules generally do not cover a product that is “essentially a copy” of an approved drug unless a prescriber documents a change that makes a significant difference for an individual patient. Talk to a clinician about contraindications including personal or family history of medullary thyroid carcinoma or MEN 2. RangeYourself does not provide medical advice, does not guarantee a prescription, and does not guarantee weight-loss results.

RangeYourself is reader-supported. We may earn a commission when you click on certain links, at no extra cost to you. Editorial recommendations are made independently. Pricing reflects publicly listed entry tiers, verified on the dates shown in the table above, and may change. Numbers like Compounded, $69/mo (limited-time promo, was $299), verified 2026-08-21; confirm current price at checkout. Standard/recurring price not publicly listed. (Same offer showed $99/mo and $149/mo promos on 2026-07-14, see price history.) and Compounded, advertised 'first month low as $49'; ongoing recurring rate not published (funnel-gated), confirm at enrollment are starting tiers, not your guaranteed long-term cost.